Eltrombopag under the brand-name drug Revolade 12.5mg. The drug is not available as a generic drug. Revolade 12.5mg drug may be needed as part of a combination therapy. Thereby drug may need to take it with other medications. Revolade 12.5mg is a prescription drug which is used under the guidance of the doctor
Revolade 12.5mg is mainly indicated for the treatment of patients having Reduced platelet levels due to chronic immune thrombocytopenia
Revolade 12.5mg is mainly indicated for the treatment of patients having reduced platelet counts due to chronic hepatitis C virus infection Revolade 12.5mg is mainly indicated for the treatment of patients having Severe aplastic Anemia
1. First line treatment of severe aplastic Anemia
2. Treatment of refractory severe aplastic Anemia
Mechanism of action
Revolade exist in class of drugs called thrombopoietin (TPO) receptor agonists.
A classification of drugs is an association of medications which work in a similar way.
These drugs are often used to treat similar conditions.
Revolade works by raise cells in bone marrow and leads these cells to make various platelets. This effect reduces the risk of bleeding.
Peak plasma concentration is 2-6 hours
Highly human plasma protein bounding is >99% and in blood plasma level is 50% to 79%
Predominantly metabolised through cleavage, oxidation and conjugation with glucuronic acid.
Revolade 12.5mg eliminated primarily via feces 59%, along with 31% via renally excreted Half-life of Revolade 12.5mg healthy patients is 21-23 hours and idiopathic thrombocytopenic purpura is 26-35 hours.
Chronic Hepatitis C-associated Thrombocytopenia:
The recommended dose: 25 mg PO qDay
Dose is Adjust in 25 mg accretion q2weeks PRN to attain target Pltneeded to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day
Severe Aplastic Anemia
1.First-line therapy :
Concomitant use with standard immunosuppressive therapy, for patients with serious aplastic Anemia (SAA) The recommended dose: 150 mg PO qDay for 6 months Do not give more thanstarting dose; total duration is 6 months
2.Refractory SAA :
The drug given for this condition who fail to respond sufficient to at least 1 before immunosuppressive therapy The recommended dose: 50 mg PO qDay Chronic Immune Thrombocytopenia The recommended dose: 50 mg PO qDay Adjust dose to achieve and control platelet count (Plt) >50 x 10^9/L to lowers risk of bleeding; not to exceed 75 mg/day
Common side effects :
• pain in head
• decreased appetite
• low red blood cells
Serious side effects:
• Abdomen swelling
• Chest pain
• Cloudy vision
• Urine in dark colour
• Yellowing of your skin
• Sensitivity to light
• Seeing circles around lights
• Swelling of legs.
If the patients have cataracts, avoid the drug due to the drug effects cataracts and make the condition worse.
Disease progression warning: Avoid using the drug while the patients have myelodysplastic syndrome (MDS), will increases the risk of death.
If other blood clot risk factors, then avoid the drug because it will increase platelet counts and blood clots.